JP2009533021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533021A5 JP2009533021A5 JP2009502214A JP2009502214A JP2009533021A5 JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5 JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nucleotide sequence
- sequence selected
- substantial homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 20
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims 2
- 102100029337 Thyrotropin receptor Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0606276.4 | 2006-03-29 | ||
| GB0606276A GB0606276D0 (en) | 2006-03-29 | 2006-03-29 | Antibodies |
| GB0607376A GB0607376D0 (en) | 2006-04-12 | 2006-04-12 | Antibodies |
| GB0607376.1 | 2006-04-12 | ||
| PCT/GB2007/001139 WO2007110648A1 (en) | 2006-03-29 | 2007-03-29 | Agonist antibodies against tshr |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533021A JP2009533021A (ja) | 2009-09-17 |
| JP2009533021A5 true JP2009533021A5 (https=) | 2010-05-13 |
| JP5165672B2 JP5165672B2 (ja) | 2013-03-21 |
Family
ID=38093407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502214A Active JP5165672B2 (ja) | 2006-03-29 | 2007-03-29 | Ｔｓｈｒに対するアゴニスト抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8603466B2 (https=) |
| EP (1) | EP1999153B1 (https=) |
| JP (1) | JP5165672B2 (https=) |
| ES (1) | ES2482145T3 (https=) |
| WO (1) | WO2007110648A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073992B2 (en) * | 2008-12-24 | 2015-07-07 | Rsr Ltd. | Human anti TSHR antibodies |
| US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| US10711282B2 (en) | 2015-11-23 | 2020-07-14 | Novartis Ag | Optimized lentiviral transfer vectors and uses thereof |
| AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20220227875A1 (en) * | 2019-05-31 | 2022-07-21 | University Of Florida Research Foundation, Incorporated | Vector-based therapy for thyroid disease |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| US20260015417A1 (en) * | 2022-06-10 | 2026-01-15 | Medimabbio Inc. | Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| CN118994398A (zh) * | 2024-09-27 | 2024-11-22 | 兰州大学第二医院 | 一种抗促甲状腺激素受体单克隆抗体7c3及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69530107T2 (de) * | 1994-12-28 | 2003-10-16 | University Of Kentucky, Lexington | Monoklonaler anti-idiotypischer antikörper 3h1 aus maus |
| US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
| AU6061700A (en) * | 1999-07-01 | 2001-01-22 | Procter & Gamble Company, The | Transparent or translucent, liquid or gel type automatic dishwashing detergent product |
| EP1456234B1 (en) * | 2001-08-23 | 2014-04-09 | Rsr Limited | Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
-
2007
- 2007-03-29 JP JP2009502214A patent/JP5165672B2/ja active Active
- 2007-03-29 ES ES07732193.3T patent/ES2482145T3/es active Active
- 2007-03-29 US US12/294,760 patent/US8603466B2/en active Active
- 2007-03-29 EP EP07732193.3A patent/EP1999153B1/en active Active
- 2007-03-29 WO PCT/GB2007/001139 patent/WO2007110648A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533021A5 (https=) | ||
| RU2009126766A (ru) | Антитела человека к дельта-подобному лиганду-4 человека | |
| JP2021535743A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| JP5972871B2 (ja) | 抗ｉｌ−２３ヘテロ二量体特異的抗体 | |
| JP7173964B2 (ja) | 抗ｐ５３抗体 | |
| JP2009502171A5 (https=) | ||
| JP2010511388A5 (https=) | ||
| RU2013107776A (ru) | Антитело к противоопухолевому антигену и способы применения | |
| FI3309176T3 (fi) | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö | |
| JP2013520174A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| JP2020530285A5 (https=) | ||
| RU2010132647A (ru) | Анти-mif антитела | |
| JP2019506155A5 (https=) | ||
| JP2012523848A5 (https=) | ||
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| CN106604932A (zh) | 人白细胞介素‑2的免疫刺激单克隆抗体 | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| Xia et al. | Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma | |
| CN108178799B (zh) | 一种抗ca125糖类抗原的纳米抗体及其应用 | |
| JP2019534892A5 (https=) | ||
| RU2009120536A (ru) | Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf) | |
| CN114853888A (zh) | 抗tslp纳米抗体及其应用 |